Spyre Therapeutics (SYRE) EBITDA Margin Growth (1y) (2016 - 2023)
Powered by 
Analysis
Spyre Therapeutics (SYRE) EBITDA Margin Growth (1y) (2016 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -1,651.00 |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 29,091.00 |
| 10 | Spyre Therapeutics | 7.51 Bn | 7.51 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -1.96 Mn |
| Mar 31, 2023 | -770,349.00 |
| Dec 31, 2022 | -1.08 Mn |
| Sep 30, 2022 | -1.06 Mn |
| Jun 30, 2022 | -353,872.00 |
| Jun 30, 2018 | 4,772.00 |
| Mar 31, 2018 | 9,868.00 |
| Dec 31, 2017 | -236.00 |
| Sep 30, 2017 | -8,587.00 |
| Jun 30, 2017 | -5,414.00 |
| Mar 31, 2017 | -11,304.00 |
| Dec 31, 2016 | -19,233.00 |
| Sep 30, 2016 | -22,994.00 |
| Jun 30, 2016 | -35,843.00 |